{"ticker": {"uuid": "7a440876-d01c-4de4-9256-e2c68e30a51b", "symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "exchange": "SAO", "country": "BR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1lheGxqRDBaVVA1RVB4LUFuNGpUczNSNU1EWU81RUY0Q3JEcXZOUm9XQURNVkREU1ZrUENqbDdtcjA4RWVMVFlLN0dEVjBYYk4xeVBGS2RBYzNFOXdIMENxLTJVWVB1MlBFZjBDVnpZTWQ5RzZiN2w3YXdzZkM0eXZCcEI5ZnpnQW1iRVVrZXRWcV9YdlJjX3JKQkpWcGhyazEtd2hBVGFqdUZXdGV4NkVvenNMMjBa?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:54:59+00:00", "published_display": "14 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin stock surges on positive hypochondroplasia trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNX1htQWhhU3BDWGFSeHBZRmR2MENna3lTUE53TXFKUlFtYlZpUGJCSUNJaEJJUlR5ME4tclcwR1c4bDZtOHFnNno0aUduUWY0TFFtd1B5bGNmOURfWDQ5WHdCTW9aYkFlZzJBWkJJcU56ZHBxaU1xZ21nMk5Ub2JzZnlGNW5tOUIzcmIzbXRfcUdLN3M5M3h1eW4xTXRBRS1DWmV4TjVDUFNQZ21xcC1vdUZSbTlvT2x1N2NqS2VIWWJwZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin stock hits 52-week low at 50.75 USD By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONGM1UDZocXhYb084bXNBR2JzTkc5c0JIY2lxQ2dGekUzVjJNVVY4ZnRTWE5mOF91NlRWRXlUUnVuNGJ0Z00wa2hBNXk0VTVmTWZiNm5oazR4UkRSbVBhdnE4MTYzRXZVWjRBMnFsVldwS2p3SXZSYzdMc1BVNGNnUjVJeWxEeHNicF9lVV8wQVNkQ3RsRE5GalU0WXViUjg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNU2xERzRheUhHR3M1c2MtZzg1bEllUFVVcmpoMnFwVFFaSlBDdWxENWRBR2FFbVQxVFE1S2VxVDNSY3F5VzBubUE0THhCVFFjU2FLUHJKZjBFNUVoa2lFYnBkcWY1cW1iWDNJbUk5V1FwS1Z3WTlqakJScFZIaWU1aXZEZDdUOThaS1R3ZUoxV3gwUDNNRmNHYjhBY3luRWI1UWFIYm1jZ21GbjJnRHExT0M5OEFBMjNYVU9zMkJpdWFaUVFnbzlKLWdJUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes It A Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOUGN3X053bDc5MDBzTHJKWEVHelF2YzZieUdraldYU0dYSmtDM0JjSkdNVW9sZ3lFNTF5eVFRVk0yQ2lmdEUzM1J0SklrT3EtazdEN2stUE51SGY0WmJlc004dmU2V25lRjh2T0JlMVptcDMwd2Y0NkNiZlZ3c0M4Yk1TM3UtYkZTSzEtMzZyUGoyZk1GMVVGWEhWUkhleFJCeXFKejh4ZHpuWHAzV2w4RG5uY3F0cVp2Qmt4azZEVHNua0d2MVR3Q3J1bEVWckpN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist reiterates Buy on BioMarin stock amid new competition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNR2NPQlRMWlNTcWUzcnE3U24tblRpVGZnMTBHTDFla3dxOERkTndaT3hxb0FheENzV1RPNFNVRVh5VTdqRjlrb191Q2NVdF9YWEl1UkczbmZOSXgxd2tuQ21sWUxuR2I3T3QtY3h4THVLSUdDeU5PNkhVdjc1a3NOQkszTGw5ZWJMMFFDLVVReENYNURfNWg0OEZCOXg4emw1VXh0RlphMVp4bzE5ZWRxQnZvdXBUajdza201Sw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Price Target Slashed Amid New Leadership Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZ2pGdS13VFpVLUprZkRNMC02NFVKT1dqM1BhZlZQOUhOanduOTF0SEU2cjdlU25tSGotZGMxelNxX1BJeW5qazlRZFZBU1llcDNoLXRwbzFoVEdIcXF6YXhvakd3enBDSGVndGVLQUFmXzhnS0QyQlZDcWY3N3BCMTRtcUloVzdGYk5j?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVzNsNlBZR3RFdXoxdWFPNzNNU3Ftc0Vnc0QzdV9EQi05QVpUZ0J6SExTbnhXci1GNUlObFJqRjQ3QmktMW5DZkxaU0trYWgwa195WDRzYmpJSnFTSkh2NWlEZVZLZEh0OW4zdFZYeXNqdjlmY19Eb1RsUmJSSmVXRzAxRHA4VlRCb1UtZ01veHZONDgtRmpacTFHTzQ3S3lsWW1KSDYzTGdyUmtXRHZmQ2UtZjhhWUF0UmtJRkgzUmRBM245QjhLZw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces Positive Pivotal Data for PALYNZIQ\u00ae (pegvaliase-pqpz) in Adolescents with Phenylketonuria", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOblF5NnhWOVItaUFRcTdPNFVlYk9CSkpUdTFPTG1lakRTaXQ4Zkx4RmpEWkdnWER0X0YyUEJFN0Q5TmM2bXViYlBBZzhLNVpRbHlOYlJzdjR0RmVhOHpQMjdxeFVzX1dOT2d2U3F4R2pfc3BCbHdnemw4THpjZDc4dXNZLUtTdEl3NjNPY2xWZm5kMWE3c3B3eVZHdFYyYmVDYW5EUUFMZkNvZDhfQlNuenlJQ1l4X3FUcUFtZFlLZWlOVWY1QVVHejJ5Uk5UUGVrSXcxTVpGZWlsNE41U0MxNmlrOHlmd2hidGs2ZHlXTlZOLWc?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-02T07:00:00+00:00", "published_display": "02 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Stock Price Forecast. Should You Buy BMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5md2F6WWtqWkhoMjFGMjBCODRmWm51TkV1UU9PTkpMaDJtR010R2w3S1hDNXRXRVNUSW1XbWRmS0J2N3RIMnFSVw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T10:04:05+00:00", "published_display": "01 Dec 2020 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1lheGxqRDBaVVA1RVB4LUFuNGpUczNSNU1EWU81RUY0Q3JEcXZOUm9XQURNVkREU1ZrUENqbDdtcjA4RWVMVFlLN0dEVjBYYk4xeVBGS2RBYzNFOXdIMENxLTJVWVB1MlBFZjBDVnpZTWQ5RzZiN2w3YXdzZkM0eXZCcEI5ZnpnQW1iRVVrZXRWcV9YdlJjX3JKQkpWcGhyazEtd2hBVGFqdUZXdGV4NkVvenNMMjBa?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:54:59+00:00", "published_display": "14 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin stock surges on positive hypochondroplasia trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNX1htQWhhU3BDWGFSeHBZRmR2MENna3lTUE53TXFKUlFtYlZpUGJCSUNJaEJJUlR5ME4tclcwR1c4bDZtOHFnNno0aUduUWY0TFFtd1B5bGNmOURfWDQ5WHdCTW9aYkFlZzJBWkJJcU56ZHBxaU1xZ21nMk5Ub2JzZnlGNW5tOUIzcmIzbXRfcUdLN3M5M3h1eW4xTXRBRS1DWmV4TjVDUFNQZ21xcC1vdUZSbTlvT2x1N2NqS2VIWWJwZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin stock hits 52-week low at 50.75 USD By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONGM1UDZocXhYb084bXNBR2JzTkc5c0JIY2lxQ2dGekUzVjJNVVY4ZnRTWE5mOF91NlRWRXlUUnVuNGJ0Z00wa2hBNXk0VTVmTWZiNm5oazR4UkRSbVBhdnE4MTYzRXZVWjRBMnFsVldwS2p3SXZSYzdMc1BVNGNnUjVJeWxEeHNicF9lVV8wQVNkQ3RsRE5GalU0WXViUjg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNU2xERzRheUhHR3M1c2MtZzg1bEllUFVVcmpoMnFwVFFaSlBDdWxENWRBR2FFbVQxVFE1S2VxVDNSY3F5VzBubUE0THhCVFFjU2FLUHJKZjBFNUVoa2lFYnBkcWY1cW1iWDNJbUk5V1FwS1Z3WTlqakJScFZIaWU1aXZEZDdUOThaS1R3ZUoxV3gwUDNNRmNHYjhBY3luRWI1UWFIYm1jZ21GbjJnRHExT0M5OEFBMjNYVU9zMkJpdWFaUVFnbzlKLWdJUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes It A Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOUGN3X053bDc5MDBzTHJKWEVHelF2YzZieUdraldYU0dYSmtDM0JjSkdNVW9sZ3lFNTF5eVFRVk0yQ2lmdEUzM1J0SklrT3EtazdEN2stUE51SGY0WmJlc004dmU2V25lRjh2T0JlMVptcDMwd2Y0NkNiZlZ3c0M4Yk1TM3UtYkZTSzEtMzZyUGoyZk1GMVVGWEhWUkhleFJCeXFKejh4ZHpuWHAzV2w4RG5uY3F0cVp2Qmt4azZEVHNua0d2MVR3Q3J1bEVWckpN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist reiterates Buy on BioMarin stock amid new competition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNR2NPQlRMWlNTcWUzcnE3U24tblRpVGZnMTBHTDFla3dxOERkTndaT3hxb0FheENzV1RPNFNVRVh5VTdqRjlrb191Q2NVdF9YWEl1UkczbmZOSXgxd2tuQ21sWUxuR2I3T3QtY3h4THVLSUdDeU5PNkhVdjc1a3NOQkszTGw5ZWJMMFFDLVVReENYNURfNWg0OEZCOXg4emw1VXh0RlphMVp4bzE5ZWRxQnZvdXBUajdza201Sw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Price Target Slashed Amid New Leadership Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZ2pGdS13VFpVLUprZkRNMC02NFVKT1dqM1BhZlZQOUhOanduOTF0SEU2cjdlU25tSGotZGMxelNxX1BJeW5qazlRZFZBU1llcDNoLXRwbzFoVEdIcXF6YXhvakd3enBDSGVndGVLQUFmXzhnS0QyQlZDcWY3N3BCMTRtcUloVzdGYk5j?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVzNsNlBZR3RFdXoxdWFPNzNNU3Ftc0Vnc0QzdV9EQi05QVpUZ0J6SExTbnhXci1GNUlObFJqRjQ3QmktMW5DZkxaU0trYWgwa195WDRzYmpJSnFTSkh2NWlEZVZLZEh0OW4zdFZYeXNqdjlmY19Eb1RsUmJSSmVXRzAxRHA4VlRCb1UtZ01veHZONDgtRmpacTFHTzQ3S3lsWW1KSDYzTGdyUmtXRHZmQ2UtZjhhWUF0UmtJRkgzUmRBM245QjhLZw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces Positive Pivotal Data for PALYNZIQ\u00ae (pegvaliase-pqpz) in Adolescents with Phenylketonuria", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOblF5NnhWOVItaUFRcTdPNFVlYk9CSkpUdTFPTG1lakRTaXQ4Zkx4RmpEWkdnWER0X0YyUEJFN0Q5TmM2bXViYlBBZzhLNVpRbHlOYlJzdjR0RmVhOHpQMjdxeFVzX1dOT2d2U3F4R2pfc3BCbHdnemw4THpjZDc4dXNZLUtTdEl3NjNPY2xWZm5kMWE3c3B3eVZHdFYyYmVDYW5EUUFMZkNvZDhfQlNuenlJQ1l4X3FUcUFtZFlLZWlOVWY1QVVHejJ5Uk5UUGVrSXcxTVpGZWlsNE41U0MxNmlrOHlmd2hidGs2ZHlXTlZOLWc?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-02T07:00:00+00:00", "published_display": "02 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Stock Price Forecast. Should You Buy BMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5md2F6WWtqWkhoMjFGMjBCODRmWm51TkV1UU9PTkpMaDJtR010R2w3S1hDNXRXRVNUSW1XbWRmS0J2N3RIMnFSVw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T10:04:05+00:00", "published_display": "01 Dec 2020 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 64, "total_relevant": 13, "sentiment_summary": {"positive": 6, "negative": 0, "neutral": 7, "score": 58, "total": 13, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 70, "events": [{"event": "general", "label": "Market update", "weight": 2.2, "count": 4}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 142.02, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": 1.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.018892, "market_dynamics_buy_signal": false, "relative_strength": -13.627497, "fair_value_gap": -24.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 30.9275, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "PR Newswire", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Seeking Alpha", "count": 1}, {"label": "timothysykes.com", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 13}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}, {"label": "Earnings", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "70/100 classification confidence."}, {"label": "Company focus", "value": "13", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "H.C. Wainwright reiterates BioMarin stock rating at Neutral"}], "updated_at": "2026-07-18T02:31:20.457814+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}